DECIPHERA PHARMACEUTICALS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
DECIPHERA PHARMACEUTICALS INC. - More news...
DECIPHERA PHARMACEUTICALS INC. - More news...
- Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results
- Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
- Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021
- Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones
- Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor
- Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
- The Boston Globe Names Deciphera a Top Place to Work for 2020
- Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
- Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
- Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
- Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020
- Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
- Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
- Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer